EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation

Enrique Montagud-Marrahi, Adriana Rodriguez-Gonzalo, Joan Vidiella-Martin, Blanca Martin Álvarez, Irving Gaston Ramírez, Albert Baronet, Joana Ferrer-Fàbrega, Antonio J Amor, Maria José Ramírez-Bajo, Mireia Musquera, Fritz Diekmann, Pedro Ventura-Aguiar

Transplant International · 2025

DOI: 10.3389/ti.2025.15263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant International, 2025. Verfasst von Enrique Montagud-Marrahi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kidney Transplant Unit, Nephrology and Kidney Transplantation Department, Hospital Clinic of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Pancreas Transplantation, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell depleting agents and IL-2 receptor blockers are the most common induction therapies in simultaneous pancreas-kidney transplantation (SPKT), but the optimal choice remains debated. Here, we perform a retrospective, single-center study with SPKT recipients from 2000 to 2023. Basiliximab was used between 2008 and 2013, and thymoglobulin in other periods. Patients with prior transplants, calculated PRA >20%, pre-SPKT Donor-Specific Antibodies or graft primary non-function because technical reasons, were excluded. An Inverse Probability of Treatment Weighting (IPTW) was performed to adjust for confounding variables. 305 SPKT recipients were included, of which 172 (56%) received thymoglobulin and 133 (44%) basiliximab. Recipient (86% vs. 80%), pancreas (86% vs. 83%) and kidney (84% vs. 89%) death-censored graft survival at 20 years were comparable between groups. Basiliximab was not associated with an increased risk of patient death [HR 1.47 (0.69–3.14), P = 0.32], pancreas [HR 1.08 (0.55–2.10), P = 0.83] or kidney graft failure [HR 0.80 (0.38–1.70), P = 0.56] compared to thymoglobulin. Basiliximab did not significantly increase the risk of pancreas [OR 1.49 (0.84–2.63), P = 0.37] or kidney graft rejection [OR 1.31 (0.54–3.15), P = 0.20]. However, it was associated with significantly lower risk of CMV [OR 0.41 (0.23–0.72), P = 0.002] and BK virus infections [OR 0.31 (0.12–0.80), P = 0.02]. No significant difference was found in new-onset malignancy incidence. These results were maintained even after IPTW adjustment. In SPKT recipients with low immunological risk, basiliximab provides comparable long-term patient and graft outcomes to thymoglobulin while reducing the incidence of opportunistic infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreas TransplantationKidney TransplantationImmunosuppressive AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedBasiliximabAntilymphocyte SerumGraft SurvivalAdultGraft RejectionRecombinant Fusion Proteins

Stichwörter der Autor:innen

basiliximabneoplasmopportunistic infectionssimultaneous kidney pancreas transplantationthymoglobulin

Substanzen

BasiliximabImmunosuppressive AgentsAntilymphocyte SerumthymoglobulinRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Kidney Transplant Unit, Nephrology and Kidney Transplantation Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Laboratori de Nefrologia i Trasplantament (LENIT), Fundació per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Red de Investigación Cooperativa Orientada a Resultados en Salud (RICORS 2040), Madrid, Spain.
  • Nephrology Department, Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain.
  • Nephrology Department, Hospital Universitario Río Hortega, Valladolid, Spain.
  • Nephrology Department, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico.

Zitieren

APA

Montagud-Marrahi, E., Rodriguez-Gonzalo, A., Vidiella-Martin, J., Álvarez, B. M., Gaston Ramírez, I., Baronet, A., Ferrer-Fàbrega, J., Amor, A. J., Ramírez-Bajo, M. J., Musquera, M., Diekmann, F., & Ventura-Aguiar, P. (2025). Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation. Transplant International. https://doi.org/10.3389/ti.2025.15263

Vancouver

Montagud-Marrahi E, Rodriguez-Gonzalo A, Vidiella-Martin J, Álvarez BM, Gaston Ramírez I, Baronet A, et al. Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation. Transplant International. 2025. doi:10.3389/ti.2025.15263

BibTeX
@article{MontagudMarrahi2025,
  author = {Montagud-Marrahi, Enrique and Rodriguez-Gonzalo, Adriana and Vidiella-Martin, Joan and Álvarez, Blanca Martin and Gaston Ramírez, Irving and Baronet, Albert and Ferrer-Fàbrega, Joana and Amor, Antonio J and Ramírez-Bajo, Maria José and Musquera, Mireia and Diekmann, Fritz and Ventura-Aguiar, Pedro},
  title = {Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation},
  journal = {Transplant International},
  year = {2025},
  doi = {10.3389/ti.2025.15263}
}
Kostenlos starten →